User reviews

User Review - Flag as inappropriate

TorreyPine migraine drug tezampanel trials met the primary endpoint
TorreyPines medical company announced, <a href="">tezampanel</a> in 306
patients enrolled in the treatment of acute migraine attacks Single Phase IIb clinical trial meets primary endpoint.
The trial was a randomized, double-blind, placebo-controlled, parallel-group, multi-center trial, the treatment objective evaluation tezampanel single migraine attack (available without aura) effect.
The primary goal is to develop projects in Phase III, to determine the treatment of acute migraine tezampanel amount. The primary efficacy endpoint was headache medication 2 hours after the response. All doses of tezampanel migraine treatment were well tolerated with no reported severe or medically important adverse reactions. Secondary efficacy endpoints included acute migraine trials associated with the traditional end.
On the primary endpoint, with statistical significance is receiving 40mg dose treatment, 78.2% of patients with headache response is improved, while the placebo group was 58.7%.
TorreyPines Neil Kurtz, president and chief executive officer, said, "These data demonstrate that, tezampanel can relieve migraine headaches, and has a good safety and tolerability and we hope that with the U.S. Food and Drug Administration (FDA) met to discuss the tezampanel 2008 年 matters into phase III trials. "
Medchemexpress Can provide the above product,its website:<a href=""></a>
<a href="">TAK-901</a>
<a href="">SB-743921</a>
<a href="">ARRY-520</a>
<a href="">Ispinesib</a>
<a href="">AMG 900</a>
<a href="">ROCK-II inhibitor</a>
<a href="">SGI-1776</a>
<a href="">Enzastaurin</a>
<a href="">Sotrastaurin</a>
<a href="">Chelerythrine Chloride</a>

All reviews - 1
5 stars - 0
4 stars - 0
3 stars - 0
2 stars - 0
1 star - 0

All reviews - 1
Editorial reviews - 0